Supernus Pharmaceuticals, Inc. or Amphastar Pharmaceuticals, Inc.: Who Leads in Yearly Revenue?

Supernus vs. Amphastar: A Decade of Revenue Rivalry

__timestampAmphastar Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 2014210461000122045000
Thursday, January 1, 2015251519000144427000
Friday, January 1, 2016255165000215003000
Sunday, January 1, 2017240175000302238000
Monday, January 1, 2018294666000408897000
Tuesday, January 1, 2019322357000392755000
Wednesday, January 1, 2020349846000520397000
Friday, January 1, 2021437768000579775000
Saturday, January 1, 2022498987000667238000
Sunday, January 1, 2023644395000607521000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of Revenue Growth: Supernus vs. Amphastar

In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. Over the past decade, Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. have been vying for dominance. From 2014 to 2023, Supernus has consistently outpaced Amphastar, with a notable 447% increase in revenue, peaking at approximately $667 million in 2022. Amphastar, while trailing, has shown impressive growth, with a 206% increase, reaching around $644 million in 2023.

Key Insights

  • 2014-2018: Supernus began to pull ahead, doubling its revenue by 2018.
  • 2019-2023: Amphastar narrowed the gap, achieving its highest revenue in 2023.

This data highlights the dynamic nature of the pharmaceutical industry, where strategic innovation and market adaptation are crucial for sustained growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025